Sort
326,823 grants matching “clinical trial”
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
$1,954,475Laura J Esserman · University Of California, San Francisco · P01 · FY2019 · CA
MRI Based Presymptomatic Prediction of ASD
$1,954,434John R Pruett · Washington University · R01 · FY2020 · MH
Targeted Sphingolipid Metabolism for Treatment of AML
$1,954,358Thomas P Loughran · University Of Virginia · P01 · FY2022 · CA
Targeted Sphingolipid Metabolism for Treatment of AML
$1,954,358Thomas P Loughran · University Of Virginia · P01 · FY2023 · CA
cGMP Recombinant FIX for IV & Oral Hemophilia B Therapy
$1,954,305William H Velander · University Of Nebraska Lincoln · R01 · FY2006 · HL
Clinical and Behavioral Phenotyping of Autism and Related Disorders
$1,954,272Susan Swedo · National Institute Of Mental Health · ZIA · FY2013 · MH
Centers for Intervention Development and Applied Research (CIDAR)
$1,954,229William T. Carpenter · University Of Maryland Baltimore · P50 · FY2010 · MH
Noroviruses and Epidemic Gastroenteritis
$1,953,910Kim Y. Green · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Clinical trials of gene therapy for Leber congenital amaurosis
$1,953,570Samuel G Jacobson · University Of Pennsylvania · U10 · FY2007 · EY
Mechanisms of GVHD
$1,953,263Joseph H Antin · Dana-Farber Cancer Inst · P01 · FY2009 · CA
Normal & Neoplastic Growth in the Brain
$1,953,065Suzanne J Baker · St. Jude Children'S Research Hospital · P01 · FY2009 · CA
Clinical Pharmacology Quality Assurance (CPQA)
$1,952,788Gene Morse · State University Of New York At Buffalo · N01 · FY2022 · AI
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis
$1,952,701Geoffrey I Shapiro · Dana-Farber Cancer Inst · UM1 · FY2018 · CA
Immunotherapy for Ocular Surface Diseases
$1,952,701Sandeep Jain · University Of Illinois At Chicago · R24 · FY2023 · EY
Nitric Oxide and Endothelial Function in Patients with Malaria
$1,952,659Hans Ackerman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Reduced BBB Water Exchange as a Preclinical Biomarker of Small Vessel Disease
$1,952,654Brian Timothy Gold · University Of Kentucky · RF1 · FY2022 · NS
Bacteriophage-based approach for managing Shigella infections
$1,952,644Alexander Sulakvelidze · Intralytix, Inc. · U01 · FY2020 · AI
The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)
$1,952,501Judith S Hochman · New York University School Of Medicine · R01 · FY2024 · HL
Emory HIV/AIDS Clinical Trials Unit
$1,952,108Jeffrey Lennox · Emory University · UM1 · FY2012 · AI
Texas EXperimental Cancer Therapeutics Network - TEX CTN
$1,952,013Funda Meric-Bernstam · University Of Tx Md Anderson Can Ctr · UM1 · FY2023 · CA
DNA Vaccines
$1,951,994George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Mathematical Oncology Systems Analysis Imaging Center (MOSAIC)
$1,951,992Kristin R Swanson · Mayo Clinic Arizona · U54 · FY2024 · CA
Drug development of clavulanic acid, a GLT-1 activator: proof of concept for cocaine use disorder
$1,951,956Mary F. Morrison · Temple Univ Of The Commonwealth · U01 · FY2022 · DA
Basic to Clinical Molecular Neurobiology of Nicotinic Receptors in Schizophrenia
$1,951,593Robert Freedman · University Of Colorado Denver · P50 · FY2012 · MH
HIV VACCINE TRIAL CLINICAL UNIT
$1,951,570Harvard University (Medical School) · U01 · FY2005 · AI